Preparing for the future implementation of respiratory syncytial virus vaccines.,The Lancet Respiratory Medicine

当前位置： X-MOL 学术 › Lancet Respir. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Preparing for the future implementation of respiratory syncytial virus vaccines.
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2020-01-21 , DOI: 10.1016/s2213-2600(19)30478-3
Thomas C Williams ₁ , Sonnie Kim ₂ , David J Spiro ₃ , Harry Campbell ₄

Affiliation

Respiratory illness caused by respiratory syncytial virus (RSV) is increasingly recognised as a major cause of childhood morbidity and mortality globally. This increased awareness has led to the development of candidate RSV vaccines, monoclonal antibodies, and therapeutics, some of which have reached phase 2 and 3 trials. We recently organised an international workshop titled RSV Genomic Diversity and the Development of a Globally Effective RSV Intervention, at the Fogarty International Centre, National Institutes of Health (Bethesda, MD, USA) in September, 2019. A common theme that emerged was that planning the implementation of potential interventions requires a deeper understanding of RSV molecular epidemiology and the host immune response. Although several international efforts to improve our understanding are ongoing, the effectiveness of this research is hampered by the lack of a consistent approach. In this Comment, we highlight the rationale for standardising key aspects of RSV research ( ).

中文翻译：

为将来的呼吸道合胞病毒疫苗的实施做准备。

由呼吸道合胞病毒（RSV）引起的呼吸道疾病在全球范围内日益被认为是导致儿童发病和死亡的主要原因。这种认识的提高导致了候选RSV疫苗，单克隆抗体和治疗剂的开发，其中一些已进入2期和3期试验。我们最近于2019年9月在美国国立卫生研究院Fogarty国际中心（美国马里兰州贝塞斯达）举办了名为RSV基因组多样性和全球有效RSV干预的发展的国际研讨会。一个共同的主题是规划潜在干预措施的实施需要对RSV分子流行病学和宿主免疫反应有更深入的了解。尽管国际上正在进行一些努力来增进我们的了解，缺乏一致的方法阻碍了这项研究的有效性。在本评论中，我们重点介绍了标准化RSV研究关键方面的理由（）。

更新日期：2020-03-03

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文